• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

HCV LAUNCH MARKETING PARADIGM SHIFT?

Quote

Anonymous

Guest
As they race to be first to market, Brand Managers of the new HCV treatments will be challenging old launch concepts. The launch of these novel treatment changing modalities is an opportunity for pharma to change the launch paradigm to a more efficient sales process. Time will be of the essence to capture the attention of the physician and their market share. The high cost and slow moving door to door detail may very well take a back seat to an electronic introduction. Poor access to time constrained tech savy care givers provides the industry an opportunity to change the way they conduct education and disseminate information to their customers. This cannot be overlooked in the changing landscape that continues to hold less and less value on high cost low ROI sales forces. An younger higher technology capable physicians and office infrastructures.
 








Emails are a primitive form of electronic marketing and would not be considered a major source of information dissemination. One must think of a more sophisticated approach to match the way the customer looks for and receives information today. Interactive on demand tensing with societies and ACOs.
 




Anonymous said:
Emails are a primitive form of electronic marketing and would not be considered a major source of information dissemination. One must think of a more sophisticated approach to match the way the customer looks for and receives information today. Interactive on demand tensing with societies and ACOs.
Click to expand...

Oh gee, then let's try facebook ads and get a facebook page for HCV!!!!. Tee hee hee hee. Remember that stock offering was going to be a real winner just like this AbbVie drug. tee hee hee hee. Sadly, I bet they try it.
 




I a sure it will be amazing...worthy of a commercial all-summit. Too bad it will not resonate with customers.

Remember, it's cure. A few weeks here or there do not matter. Now, it's about pricing. It's always about pricing.
 




Anonymous said:
I a sure it will be amazing...worthy of a commercial all-summit. Too bad it will not resonate with customers.

Remember, it's cure. A few weeks here or there do not matter. Now, it's about pricing. It's always about pricing.
Click to expand...

So how bout we offer it to the public in a lottery? We can make all our money on the losers who purchase tickets and don't win?????????????????????????????? Oh, yeah! Who needs sales reps when we can advertise the lottery on Facebook and sell tickets online?
 








Anonymous said:
As they race to be first to market, Brand Managers of the new HCV treatments will be challenging old launch concepts. The launch of these novel treatment changing modalities is an opportunity for pharma to change the launch paradigm to a more efficient sales process. Time will be of the essence to capture the attention of the physician and their market share. The high cost and slow moving door to door detail may very well take a back seat to an electronic introduction. Poor access to time constrained tech savy care givers provides the industry an opportunity to change the way they conduct education and disseminate information to their customers. This cannot be overlooked in the changing landscape that continues to hold less and less value on high cost low ROI sales forces. An younger higher technology capable physicians and office infrastructures.
Click to expand...

So, which one of these "novel new paradigms" are you selling?
 








Anonymous said:
As they race to be first to market, Brand Managers of the new HCV treatments will be challenging old launch concepts. The launch of these novel treatment changing modalities is an opportunity for pharma to change the launch paradigm to a more efficient sales process. Time will be of the essence to capture the attention of the physician and their market share. The high cost and slow moving door to door detail may very well take a back seat to an electronic introduction. Poor access to time constrained tech savy care givers provides the industry an opportunity to change the way they conduct education and disseminate information to their customers. This cannot be overlooked in the changing landscape that continues to hold less and less value on high cost low ROI sales forces. An younger higher technology capable physicians and office infrastructures.
Click to expand...

Here's the paradigm Gilead is using so far. Where be you?
http://news.yahoo.com/experimental-drug-cures-hepatitis-c-small-trials-124512104.html
 
























Top Bottom
Back
Quote